outputs = [
    {'patient_id': 'PATIENT 10', 'drug': 'CODEINE', 'timestamp': '2026021919:06:42596611', 'risk_assessment': {'risk_label': 'Adjust Dosage', 'confidence_score': 0.2, 'severity': 'high'}, 'pharmacogenomic_profile': {'primary_gene': 'CYP2D6', 'diplotype': 'Unknown', 'phenotype': 'Unknown', 'detected_variants': [{'rs6054257': 'CYP2C9', '.': 'TPMT', 'rs6040355': 'SLCO1B1', 'microsat1': 'CYP2D6'}]}, 'clinical_recommendation': 'Due to the unknown CYP2D6 metabolizer status, use of codeine is not recommended. Consider alternative analgesics that are not significantly metabolized by CYP2D6. If codeine is deemed clinically essential, close monitoring for efficacy and adverse effects is crucial, and further comprehensive CYP2D6 genetic testing should be considered to inform treatment decisions.', 'llm_generated_explanation': {'summary': "The patient's CYP2D6 pharmacogenomic profile is unknown due to insufficient or uninterpretable genetic variant data. CYP2D6 is the primary enzyme responsible for metabolizing codeine into its active form, morphine.", 'recommendations': "Given the unknown CYP2D6 status, the patient's response to codeine cannot be reliably predicted. This presents a risk for either lack of therapeutic effect (if a Poor Metabolizer) or an increased risk of adverse drug reactions, including toxicity (if an Ultrarapid Metabolizer). Therefore, caution is strongly advised regarding codeine use."}, 'quality_metrics': {'vcf_parsing_success': True, 'extension': '.vcf', 'file_size': 0.001667022705078125}},
    {'patient_id': 'PATIENT 10', 'drug': 'WARFARIN', 'timestamp': '2026021919:06:42596611', 'risk_assessment': {'risk_label': 'Safe', 'confidence_score': 1.0, 'severity': 'none'}, 'pharmacogenomic_profile': {'primary_gene': 'CYP2C9', 'diplotype': '*1/*1', 'phenotype': 'Normal Metabolizer', 'detected_variants': [{'rs6054257': 'CYP2C9', '.': 'TPMT', 'rs6040355': 'SLCO1B1', 'microsat1': 'CYP2D6'}]}, 'clinical_recommendation': 'Based on the CYP2C9 Normal Metabolizer phenotype, initiate warfarin therapy using standard dosing algorithms. Continue routine INR monitoring and clinical management as per established guidelines for all warfarin-treated patients. No specific pharmacogenomic-guided dose adjustments are warranted due to the CYP2C9 genotype.', 'llm_generated_explanation': {'summary': 'The patient is a CYP2C9 Normal Metabolizer (*1/*1), inferred from the rs6054257 G/G genotype (reference allele). For warfarin, CYP2C9 Normal Metabolizers are expected to metabolize warfarin at a normal rate, leading to predictable drug exposure.', 'recommendations': 'No specific pharmacogenomic-guided dose adjustments are typically required based on CYP2C9 genotype alone. Standard warfarin dosing and routine INR monitoring are recommended.'}, 'quality_metrics': {'vcf_parsing_success': True, 'extension': '.vcf', 'file_size': 0.001667022705078125}}
]
single ={'patient_id': 'PATIENT 10', 'drug': 'CODEINE', 'timestamp': '2026021919:06:42596611', 'risk_assessment': {'risk_label': 'Toxic', 'confidence_score': 0.2, 'severity': 'high'}, 'pharmacogenomic_profile': {'primary_gene': 'CYP2D6', 'diplotype': 'Unknown', 'phenotype': 'Unknown', 'detected_variants': [{'rs6054257': 'CYP2C9', '.': 'TPMT', 'rs6040355': 'SLCO1B1', 'microsat1': 'CYP2D6'}]}, 'clinical_recommendation': 'Due to the unknown CYP2D6 metabolizer status, use of codeine is not recommended. Consider alternative analgesics that are not significantly metabolized by CYP2D6. If codeine is deemed clinically essential, close monitoring for efficacy and adverse effects is crucial, and further comprehensive CYP2D6 genetic testing should be considered to inform treatment decisions.', 'llm_generated_explanation': {'summary': "The patient's CYP2D6 pharmacogenomic profile is unknown due to insufficient or uninterpretable genetic variant data. CYP2D6 is the primary enzyme responsible for metabolizing codeine into its active form, morphine.", 'recommendations': "Given the unknown CYP2D6 status, the patient's response to codeine cannot be reliably predicted. This presents a risk for either lack of therapeutic effect (if a Poor Metabolizer) or an increased risk of adverse drug reactions, including toxicity (if an Ultrarapid Metabolizer). Therefore, caution is strongly advised regarding codeine use."}, 'quality_metrics': {'vcf_parsing_success': True, 'extension': '.vcf', 'file_size': 0.001667022705078125}},
m ={'patient_id': 'PATIENT 10', 'drug': 'WARFARIN', 'timestamp': '2026021919:06:42596611', 'risk_assessment': {'risk_label': 'Toxic', 'confidence_score': 1.0, 'severity': 'none'}, 'pharmacogenomic_profile': {'primary_gene': 'CYP2C9', 'diplotype': '*1/*1', 'phenotype': 'Normal Metabolizer', 'detected_variants': [{'rs6054257': 'CYP2C9', '.': 'TPMT', 'rs6040355': 'SLCO1B1', 'microsat1': 'CYP2D6'}]}, 'clinical_recommendation': 'Based on the CYP2C9 Normal Metabolizer phenotype, initiate warfarin therapy using standard dosing algorithms. Continue routine INR monitoring and clinical management as per established guidelines for all warfarin-treated patients. No specific pharmacogenomic-guided dose adjustments are warranted due to the CYP2C9 genotype.', 'llm_generated_explanation': {'summary': 'The patient is a CYP2C9 Normal Metabolizer (*1/*1), inferred from the rs6054257 G/G genotype (reference allele). For warfarin, CYP2C9 Normal Metabolizers are expected to metabolize warfarin at a normal rate, leading to predictable drug exposure.', 'recommendations': 'No specific pharmacogenomic-guided dose adjustments are typically required based on CYP2C9 genotype alone. Standard warfarin dosing and routine INR monitoring are recommended.'}, 'quality_metrics': {'vcf_parsing_success': True, 'extension': '.vcf', 'file_size': 0.001667022705078125}}
